3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
120
Squamous Cell Carcinoma of Head and Neck
61
Melanoma
57
Parkinson Disease 4, Autosomal Dominant Lewy Body
47
Lung Neoplasms
45
Triple Negative Breast Neoplasms
44
Neoplasm Metastasis
42
Breast Neoplasms
40
Neoplasms
36
Colorectal Neoplasms
31
Head and Neck Neoplasms
27
Endometrial Neoplasms
26
Carcinoma, Renal Cell
26
Ovarian Neoplasms
23
Carcinoma, Transitional Cell
22
Urinary Bladder Neoplasms
21
Stomach Neoplasms
15
Pancreatic Neoplasms
14
Carcinoma
14
Uterine Cervical Neoplasms
12
Recurrence
12
Esophageal Neoplasms
12
Sarcoma
11
Hodgkin Disease
11
Brain Neoplasms
11
Carcinoma, Squamous Cell
10
Cholangiocarcinoma
9
Carcinoma, Hepatocellular
9
Skin Neoplasms
8
Esophageal Squamous Cell Carcinoma
8
Interventions
pembrolizumab
1
Pemetrexed
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
pembrolizumab
×
90 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled